-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DVSkV4YuFSjEuKI4HqozXc8K2WaJg8Trzm0ezgQP7sAysDh0tPIUFDCFBAzsb1tS +N07wtEPWNOCmlW1qYsuWA== 0001104659-08-018422.txt : 20080318 0001104659-08-018422.hdr.sgml : 20080318 20080318211826 ACCESSION NUMBER: 0001104659-08-018422 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080318 FILED AS OF DATE: 20080318 DATE AS OF CHANGE: 20080318 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SANDERLING V LTD PARTNERSHIP CENTRAL INDEX KEY: 0001267960 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33993 FILM NUMBER: 08697880 MAIL ADDRESS: STREET 1: 400 SOUTH EL CAMINO REAL STE 1200 CITY: SAN MATEO STATE: CA ZIP: 94402-1708 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CARDIONET INC CENTRAL INDEX KEY: 0001113784 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330604557 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1010 SECOND AVENUE CITY: SAN DIEGO STATE: CA ZIP: 92101 BUSINESS PHONE: (619) 243-7500 MAIL ADDRESS: STREET 1: 1010 SECOND AVENUE CITY: SAN DIEGO STATE: CA ZIP: 92101 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP CENTRAL INDEX KEY: 0001139814 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33993 FILM NUMBER: 08697877 BUSINESS ADDRESS: STREET 1: 2730 SAND HILL ROAD STREET 2: SUITE 400 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 6508549855 MAIL ADDRESS: STREET 1: 400 S EL CAMINO REAL STREET 2: STE 1200 CITY: SAN MATEO STATE: CA ZIP: 94402-1708 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SANDERLING V BETEILIGUNGS GMBH & CO KG CENTRAL INDEX KEY: 0001169312 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33993 FILM NUMBER: 08697878 BUSINESS ADDRESS: STREET 1: 2730 SAND HILL ROAD STREET 2: SUITE 200 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-854-9855 MAIL ADDRESS: STREET 1: 400 SOUTH EL CAMINO REAL STREET 2: STE 1200 CITY: SAN MATEO STATE: CA ZIP: 94402-1708 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanderling Venture Partners V Co Investment Fund, LP CENTRAL INDEX KEY: 0001316918 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33993 FILM NUMBER: 08697881 BUSINESS ADDRESS: STREET 1: 400 SOUTH EL CAMINO REAL STREET 2: SUITE 1200 CITY: SAN MATEO STATE: CA ZIP: 94402 BUSINESS PHONE: 650-401-2000 MAIL ADDRESS: STREET 1: 400 SOUTH EL CAMINO REAL STREET 2: SUITE 1200 CITY: SAN MATEO STATE: CA ZIP: 94402 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanderling Venture Partners IV, L.P. CENTRAL INDEX KEY: 0001318131 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33993 FILM NUMBER: 08697879 BUSINESS ADDRESS: STREET 1: 400 SOUTH EL CAMINO REAL STREET 2: SUITE 1200 CITY: SAN MATEO STATE: CA ZIP: 94402-7073 BUSINESS PHONE: 650-401-2011 MAIL ADDRESS: STREET 1: 400 SOUTH EL CAMINO REAL STREET 2: SUITE 1200 CITY: SAN MATEO STATE: CA ZIP: 94402-7073 3 1 a3.xml 3 X0202 3 2008-03-18 0 0001113784 CARDIONET INC BEAT 0001318131 Sanderling Venture Partners IV, L.P. 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO CA 94402 0 0 1 0 0001169312 SANDERLING V BETEILIGUNGS GMBH & CO KG 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO CA 94402 0 0 1 0 0001139814 SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO CA 94402 0 0 1 0 0001316918 Sanderling Venture Partners V Co Investment Fund, LP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO CA 94402 0 0 1 0 0001267960 SANDERLING V LTD PARTNERSHIP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO CA 94402 0 0 1 0 Series C Convertible Preferred Stock Common Stock 53721 I See footnotes Series C Convertible Preferred Stock Common Stock 223839 I See footnotes Series C Convertible Preferred Stock Common Stock 60374 I See footnotes Series C Convertible Preferred Stock Common Stock 369209 I See footnotes Series D Convertible Preferred Stock Common Stock 11281 I See footnotes Series D Convertible Preferred Stock Common Stock 47006 I See footnotes Series D Convertible Preferred Stock Common Stock 12679 I See footnotes Series D Convertible Preferred Stock Common Stock 77534 I See footnotes Warrants to Purchase Series D-1 Convertible Preferred Stock 3.50 Common Stock 27844 I See footnotes Warrants to Purchase Series D-1 Convertible Preferred Stock 3.50 Common Stock 116019 I See footnotes Warrants to Purchase Series D-1 Convertible Preferred Stock 3.50 Common Stock 31293 I See footnotes Warrants to Purchase Series D-1 Convertible Preferred Stock 3.50 Common Stock 191369 I See footnotes Mandatorily Convertible Preferred Stock Common Stock 170 I See footnotes Mandatorily Convertible Preferred Stock Common Stock 707 I See footnotes Mandatorily Convertible Preferred Stock Common Stock 191 I See footnotes Mandatorily Convertible Preferred Stock Common Stock 1165 I See footnotes Series C Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of one share of Common Stock for every two shares of Series C Preferred Stock, for no additional consideration. By Sanderling V Beteilingungs GmbH & Co KG. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Beteilingungs GmbH & Co KG and has voting and investment power over the shares held by Sanderling V Beteilingungs GmbH & Co KG. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. By Sanderling V Biomedical Co-Investment Fund L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Biomedical Co-Investment Fund L.P and has voting and investment power over the shares held by Sanderling V Biomedical Co-Investment Fund L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. By Sanderling V Limited Partnership. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Limited Partnership and has voting and investment power over the shares held by Sanderling V Limited Partnership. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. By Sanderling Venture Partners V Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling Venture Partners V Co-Investment Fund, L.P and has voting and investment power over the shares held by Sanderling Venture Partners V Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Series D Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of one share of Common Stock for every two shares of Series D Preferred Stock, for no additional consideration. Warrants became exercisable on March 8, 2007. Warrants to purchase Series D-1 Convertible Preferred will be automatically net exercised immediately prior to the closing of the Issuer's initial public offering. Series D-1 Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of one share of Common Stock for every two shares of Series D-1 Preferred Stock, for no additional consideration. Mandatorily Convertible Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of one share of Mandatorily Convertible Preferred Stock for every 66.88 shares of Common Stock, for no additional consideration. See Ex. 99.1 2008-03-17 EX-99.1 2 ex-99d1.htm EX-99.1

EXHIBIT 99.1

SANDERLING VENTURE PARTNERS IV, L.P. By: Middleton-McNeil Associates IV, L.P.		SANDERLING VENTURE PARTNERS V CO-INVESTMENT FUND, L.P.
		By: Middleton, McNeil & Mills Associates V, LLC

By:	/s/ Fred A. Middleton
Fred A. Middleton		By:	/s/ Fred A. Middleton
General Partner		Fred A. Middleton
		Managing Director

SANDERLING V BETEILIGUNGS GMBH & CO. KG		SANDERLING V LIMITED PARTNERSHIP
By: Middleton, McNeil & Mills Associates V, LLC		By: Middleton, McNeil & Mills Associates V, LLC


By:	/s/ Fred A. Middleton	By:	/s/ Fred A. Middleton
Fred A. Middleton		Fred A. Middleton
Managing Director		Managing Director

SANDERLING V BIOMEDICAL CO-INVESTMENT FUND, L.P.
By: Middleton, McNeil & Mills Associates V, LLC


By:	/s/ Fred A. Middleton
Fred A. Middleton
Managing Director

-----END PRIVACY-ENHANCED MESSAGE-----